JP2017509647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509647A5 JP2017509647A5 JP2016557982A JP2016557982A JP2017509647A5 JP 2017509647 A5 JP2017509647 A5 JP 2017509647A5 JP 2016557982 A JP2016557982 A JP 2016557982A JP 2016557982 A JP2016557982 A JP 2016557982A JP 2017509647 A5 JP2017509647 A5 JP 2017509647A5
- Authority
- JP
- Japan
- Prior art keywords
- activin
- item
- composition
- antibody
- gdf11
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 92
- 108010023079 activin B Proteins 0.000 claims description 72
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 71
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 71
- 108010059616 Activins Proteins 0.000 claims description 39
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 39
- 239000000488 activin Substances 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 108010023082 activin A Proteins 0.000 claims description 28
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 20
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 20
- -1 Nodal Proteins 0.000 claims description 20
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 18
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 18
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 18
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 18
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 18
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 18
- 208000007502 anemia Diseases 0.000 claims description 17
- 101150019176 GDF10 gene Proteins 0.000 claims description 16
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 claims description 16
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims description 15
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 claims description 15
- 210000003743 erythrocyte Anatomy 0.000 claims description 15
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims description 13
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims description 13
- 230000011664 signaling Effects 0.000 claims description 13
- 238000000423 cell based assay Methods 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 7
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 6
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 5
- 102000057208 Smad2 Human genes 0.000 claims description 5
- 208000002903 Thalassemia Diseases 0.000 claims description 5
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 3
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 23
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 145
- 125000003275 alpha amino acid group Chemical group 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 26
- 108091033319 polynucleotide Proteins 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 108091030071 RNAI Proteins 0.000 description 12
- 230000009368 gene silencing by RNA Effects 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 108091027967 Small hairpin RNA Proteins 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- 239000004055 small Interfering RNA Substances 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000000074 antisense oligonucleotide Substances 0.000 description 6
- 238000012230 antisense oligonucleotides Methods 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 208000005980 beta thalassemia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969073P | 2014-03-21 | 2014-03-21 | |
| US61/969,073 | 2014-03-21 | ||
| US201462021923P | 2014-07-08 | 2014-07-08 | |
| US62/021,923 | 2014-07-08 | ||
| PCT/US2015/021880 WO2015143403A1 (en) | 2014-03-21 | 2015-03-20 | Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020077142A Division JP7154250B2 (ja) | 2014-03-21 | 2020-04-24 | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017509647A JP2017509647A (ja) | 2017-04-06 |
| JP2017509647A5 true JP2017509647A5 (OSRAM) | 2018-04-26 |
Family
ID=54145413
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016557982A Withdrawn JP2017509647A (ja) | 2014-03-21 | 2015-03-20 | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| JP2020077142A Active JP7154250B2 (ja) | 2014-03-21 | 2020-04-24 | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020077142A Active JP7154250B2 (ja) | 2014-03-21 | 2020-04-24 | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160046690A1 (OSRAM) |
| EP (1) | EP3119418B1 (OSRAM) |
| JP (2) | JP2017509647A (OSRAM) |
| KR (2) | KR102520970B1 (OSRAM) |
| CN (1) | CN106659769A (OSRAM) |
| AU (3) | AU2015231022B2 (OSRAM) |
| CA (1) | CA2942954A1 (OSRAM) |
| MA (1) | MA39722A (OSRAM) |
| WO (1) | WO2015143403A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| ES2884095T3 (es) | 2012-11-02 | 2021-12-10 | Celgene Corp | Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos |
| WO2016069925A1 (en) | 2014-10-30 | 2016-05-06 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| AU2015358469B2 (en) | 2014-12-03 | 2021-05-27 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for treating anemia |
| SG10201913747PA (en) | 2015-04-22 | 2020-03-30 | Biogen Ma Inc | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| AU2016359695A1 (en) | 2015-11-23 | 2018-06-14 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| PL3490582T3 (pl) | 2016-07-27 | 2024-09-23 | Acceleron Pharma Inc. | Kompozycje do zastosowania w leczeniu mielofibrozy |
| EP3512887B1 (en) * | 2016-09-15 | 2024-07-31 | Acceleron Pharma Inc. | A fusion protein for use in treating anemia comprising twsg and fc |
| CN110036025B (zh) * | 2016-10-05 | 2024-03-22 | 阿塞勒隆制药公司 | 变体ActRIIB蛋白及其用途 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| PT3638243T (pt) | 2017-06-14 | 2024-10-31 | Celgene Corp | Métodos para tratamento da mielofibrose e anemia associadas ao neoplasma mieloproliferativo |
| CN107828719B (zh) * | 2017-09-14 | 2020-05-19 | 暨南大学 | Gdf11在脂肪间充质干细胞成骨分化中的应用 |
| JP7258021B2 (ja) | 2017-11-09 | 2023-04-14 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体を含む医薬組成物 |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| US12263205B2 (en) | 2018-04-30 | 2025-04-01 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| CN112601538B (zh) | 2018-05-09 | 2025-08-19 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| JP7663882B6 (ja) * | 2020-01-20 | 2025-06-10 | ルダキュア コーポレーション | Ｔｒｐｖ１活性媒介疾患治療用の薬学的組成物 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4514971A1 (en) * | 2022-04-29 | 2025-03-05 | University Of Massachusetts | Selective rna-modulating agents |
| WO2025040002A1 (zh) * | 2023-08-21 | 2025-02-27 | 苏州炫景生物科技有限公司 | 靶向inhbe基因的双链寡核苷酸、缀合物、组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2007004243A0 (en) * | 2005-04-25 | 2007-12-31 | Pfizer | Antibodies to myostatin |
| US8128933B2 (en) * | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| PL2124999T3 (pl) * | 2006-12-18 | 2013-03-29 | Acceleron Pharma Inc | Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości |
| HRP20191109T1 (hr) * | 2008-08-14 | 2019-09-20 | Acceleron Pharma Inc. | Gdf klopke za uporabu u liječenju anemije |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| AU2010258931B2 (en) * | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| KR101882521B1 (ko) * | 2009-08-13 | 2018-07-27 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| EA202090053A3 (ru) * | 2011-10-17 | 2020-06-30 | Акселерон Фарма, Инк. | Способы и композиции для лечения неэффективного эритропоэза |
| WO2013164444A1 (en) * | 2012-05-03 | 2013-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation |
| AU2013334660B2 (en) * | 2012-10-24 | 2018-08-09 | Celgene Corporation | Methods for treating anemia |
-
2015
- 2015-03-20 JP JP2016557982A patent/JP2017509647A/ja not_active Withdrawn
- 2015-03-20 CA CA2942954A patent/CA2942954A1/en active Pending
- 2015-03-20 AU AU2015231022A patent/AU2015231022B2/en not_active Ceased
- 2015-03-20 EP EP15765863.4A patent/EP3119418B1/en active Active
- 2015-03-20 MA MA039722A patent/MA39722A/fr unknown
- 2015-03-20 KR KR1020227044659A patent/KR102520970B1/ko active Active
- 2015-03-20 US US14/664,651 patent/US20160046690A1/en not_active Abandoned
- 2015-03-20 WO PCT/US2015/021880 patent/WO2015143403A1/en not_active Ceased
- 2015-03-20 KR KR1020167029253A patent/KR20160127148A/ko not_active Ceased
- 2015-03-20 CN CN201580024704.5A patent/CN106659769A/zh active Pending
-
2020
- 2020-04-24 JP JP2020077142A patent/JP7154250B2/ja active Active
- 2020-07-02 US US16/919,377 patent/US20210155672A1/en not_active Abandoned
-
2021
- 2021-01-19 AU AU2021200301A patent/AU2021200301A1/en not_active Abandoned
-
2023
- 2023-08-23 AU AU2023219885A patent/AU2023219885A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509647A5 (OSRAM) | ||
| JP6242847B2 (ja) | 血管増殖性疾患の治療 | |
| JP2017523140A5 (OSRAM) | ||
| US8426562B2 (en) | Methods and compositions for modulating tumor cell activity | |
| JP2017516756A5 (OSRAM) | ||
| TR201808018T4 (tr) | Anti-B7-H3 antikoru. | |
| AU2011201436A1 (en) | Inhibitors of angiopoietin-like 4 protein, combinations, and their use | |
| JP2016508984A5 (OSRAM) | ||
| US10106601B2 (en) | Inhibition of PLGF to treat philadelphia chromosome positive leukemia | |
| WO2009116670A1 (ja) | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 | |
| JP2015516370A5 (OSRAM) | ||
| Bucher et al. | Antibody-mediated inhibition of Tspan12 ameliorates vasoproliferative retinopathy through suppression of β-catenin signaling | |
| US9963514B2 (en) | BAG3 receptor binding molecules for use as a medicament | |
| Eleftheriou et al. | Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling | |
| CA2762446C (en) | Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis | |
| WO2021140173A1 (en) | Methods and uses for treating fibrotic solid tumors with bags inhibitors | |
| Liu et al. | Potential role of axonal chemorepellent Slit2 in modulating adventitial inflammation in a rat carotid artery balloon injury model | |
| Hyde et al. | Finding New Partnerships: The Function of Individual Extracellular Receptor Domains in Angiogenic Signalling by VEGF Receptors | |
| Münch et al. | The dimeric platelet collagen receptor GPVI-Fc reduces | |
| NZ616809B2 (en) | Anti-b7-h3 antibody |